Analysts Anticipate Cumberland Pharmaceuticals, Inc. (CPIX) to Post ($0.08) Earnings Per Share
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $12.25 for the company and are predicting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also assigned Cumberland Pharmaceuticals an industry rank of 83 out of 256 based on the ratings given to its competitors.
CPIX has been the subject of a number of research reports. Zacks Investment Research cut shares of Cumberland Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 6th. TheStreet raised shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, April 10th.
Shares of CPIX stock opened at $6.40 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.07 and a quick ratio of 1.69. The firm has a market cap of $99.36 million, a P/E ratio of -53.33 and a beta of 0.28. Cumberland Pharmaceuticals has a 12 month low of $4.83 and a 12 month high of $7.00.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.22. The firm had revenue of $11.90 million during the quarter, compared to the consensus estimate of $10.70 million. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.54%. On average, sell-side analysts anticipate that Cumberland Pharmaceuticals will post 0.37 earnings per share for the current year.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Recommended Story: Compound Interest and Why It Matters When Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.